Polaris Market Research today released findings from its latest industry report, projecting the Europe Clinical Laboratory Tests market to expand from USD 68.54 Billion in 2024 to USD 85.21 Billion by 2034, registering a CAGR of 2.21% across the forecast period. The report profiles 10 leading companies operating across the market's key segments and regions.
Analyst Commentary on Europe Clinical Laboratory Tests Market Growth
"Europe's aging population and the EU's IVDR framework are together reshaping how laboratory testing is delivered, prioritizing both quality standardization and faster access to diagnostics" said a senior analyst at Polaris Market Research. "The UK stands out as the fastest-growing market in our coverage, driven by digital health adoption and an aggressive push into genomic testing"
Key Growth Drivers, Major Companies and Segments Covered
Growth Drivers: a rapidly aging population, which the World Health Organization projects will grow from 215 million people aged 60 and above in 2021 to over 300 million by 2050, and EU-wide regulatory harmonization under the In Vitro Diagnostic Regulation (IVDR) are the primary forces behind the market's expansion, alongside rising demand for AI-driven diagnostics and advanced sequencing technologies. In April 2025, NEC Laboratories Europe and Data-Driven.AI announced a collaboration to apply AI to earlier disease detection in laboratory diagnostics.
Major Companies Covered:
- Cerba HealthCare
- Fresenius Medical Care
- LGC Limited
- Merck KgaA
- QIAGEN
- Siemens Healthineers AG
- Synlab International GmbH
- UNILABS
Request for a sample copy of this research report @
https://www.polarismarketresearch.com/industry-analysis/europe-clinical-laboratory-tests-market
Segments Covered: By Type (Clinical Chemistry Testing, Hematology Testing, Immunology & Serology Testing, Molecular Diagnostics, Others), By End Use (Central Laboratories, Primary Clinics), By Country.
Recent Developments in the Europe Clinical Laboratory Tests Market
- April 2025: NEC Laboratories Europe partnered with Data-Driven.AI to advance AI-supported preventive diagnostics for earlier disease detection.
- April 2024: Unilabs adopted SOPHiA GENETICS' AI platform to speed genomic analysis for solid tumor HRD-status testing across its Swiss diagnostic network.
Regional Snapshot: Germany Leads, UK Grows Fastest
Germany held the largest share of the Europe clinical laboratory tests market in 2024 at 21.97%, supported by its advanced healthcare infrastructure and strong preventive-care culture. The UK market is forecast to grow fastest, at an 8.5% CAGR through 2034, as digital health adoption and genomic testing initiatives expand access to personalized diagnostics. Across the region, primary clinics are also gaining share from central laboratories as point-of-care testing becomes more widely available.
Why It Matters for Teams Evaluating Diagnostics Market Entry
For stakeholders researching Europe clinical laboratory tests market forecast, the underlying Polaris Market Research report benchmarks Europe Clinical Laboratory Tests market share, company positioning, and segment-level forecasts to support sourcing, partnership, and investment decisions through 2034.
Conclusion
Europe's clinical laboratory tests market is growing more gradually than its U.S. counterpart, but the underlying drivers — an aging population, chronic disease burden, and regulatory harmonization under the IVDR — are just as structural. With Germany anchoring scale and the UK leading growth through digital and genomic innovation, the region offers a stable, quality-driven opportunity for diagnostics providers willing to navigate its regulatory landscape.
More Trending Latest Reports By Polaris Market Research:
Industrial IoT (IIoT) is bringing Transformation across Industries Worldwide
Parkinson’s Disease Treatment Market